During the Phase III BROOKLYN trial, patients were randomly assigned in a 2:1 ratio to receive either obicetrapib 10mg or a ...

There was an increase in dyslipidemia incidence during the COVID-19 pandemic compared with the prepandemic period, according ...

The Cardiovascular Prevention CME Program aligns with the First Pillar of the Malaysian Health White Paper, which is aimed a ...

SARS-CoV-2 disrupts cholesterol metabolism by using its ORF3a protein to sequester cholesterol in lysosomes, reducing BMP ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

Dietary niacin intake reduces risks of all-cause and cardiovascular mortality in US adults, with benefits more pronounced in ...

Virtually all studies have shown very high safety profiles for nutritional supplements in the treatment of dyslipidemia. In the section below, all the efficacy studies, adverse effects and safety ...

ManipalCigna Health introduces 'Sarvah' health insurance plan targeting India's 'missing middle' with customizable coverage ...

There is a clear link between these two. The common metabolic disorders are obesity, diabetes, hypertension, dyslipidemia, or ...